The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1.
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Oncoceutics; p53-Therapeutics
Consulting or Advisory Role - Morphotek
Patents, Royalties, Other Intellectual Property - I hold patents and have submitted patents relevant to my academic laboratory research. However, these patent have no relationship with my GI ASCO presentation.
 
Joanne Xiu
Employment - Caris Life Sciences
 
Elias Obeid
No Relationships to Disclose
 
Ranee Mehra
No Relationships to Disclose
 
Igor A. Astsaturov
No Relationships to Disclose
 
Jessica Wagner
No Relationships to Disclose
 
Avital Lev
No Relationships to Disclose
 
Marie Baumeister
No Relationships to Disclose
 
Anthony Frank Shields
No Relationships to Disclose
 
Mohamed E. Salem
No Relationships to Disclose
 
Jimmy J. Hwang
Consulting or Advisory Role - Amgen; Bayer; Genentech/Roche; Lilly; Merrimack; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Genentech/Roche
Expert Testimony - Roche
 
Namrata Vijayvergia
No Relationships to Disclose
 
Crystal Shereen Denlinger
Consulting or Advisory Role - Lilly; Merrimack
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst); Pfizer (Inst)
 
Efrat Dotan
No Relationships to Disclose
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
Research Funding - Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Caris Life Sciences; Celgene; Sirtex Medical
Consulting or Advisory Role - Caris Life Sciences; Celgene; Perthera; Sirtex Medical
Research Funding - Celldex (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Perthera; Sirtex Medical
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merrimack; Novartis; Roche; Sanofi
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merrimack; novartis
Speakers' Bureau - amgen; Bayer; Celgene; roche; sanofi
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
 
John Marshall
Honoraria - Amgen; Bayer/Onyx; Boehringer Ingelheim; Daiichi Sankyo; Genentech/Roche
Consulting or Advisory Role - Amgen; Bayer/Onyx; Boehringer Ingelheim; Daiichi Sankyo; Genentech/Roche
Speakers' Bureau - Amgen; Bayer/Onyx; Genentech/Roche
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst)
 
Steven J. Cohen
Consulting or Advisory Role - Bayer; Genentech; Taiho Pharmaceutical